Biotech Values

[oc631]

However, this plaintiffs’ argument won’t gain much traction with judges and juries if GILD is not promoting Truvada for prevention.

GILD sponsoring the study to expand the Truvada label towards prophylaxis use appears to be another form of promotion.

I agree the decision to not promote the drug post-approval is to contain liability issues yet GILD still may be at risk.